API | brodalumab

brodalumab (siliq) Report issue

Biologics mAb Approved ^FDA First in Class

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH

Active Ingredient History

NOW

Brodalumab, sold under the brand name Siliq in the US and Kyntheum in the EU, is a human monoclonal antibody designed for the treatment of inflammatory diseases. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
brodalumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Interleukin-17 receptor A (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$1288.1550 - $1494.9750

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

amg 827 | amg-827 | brodalumab | khk4827 | siliq

Organizations (15)

Research & Development (15)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (9)

Approved Indications (1)

Psoriasis

Experimental Indications - Clinical Trial Phases 1-4 (9)

Arthritis, Psoriatic (Phase 4)

Arthritis, Rheumatoid (Phase 2)

Asthma (Phase 2)

Axial Spondyloarthritis (Phase 3)

Crohn Disease (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Psoriasis ()

Scleroderma, Systemic (Phase 1)

Sclerosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 46
# of Trial Organizations: 15

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue